Disease Research

 
Stock Quotes for Disease Research top ^
  • Industry: Diagnostics & Research
  • Sector: Healthcare
Sign-up for htds investment picks

 
News Articles for Disease Research top ^
Highlights include additional analyses from Phase 3 and ongoing open-label studies, discovery research on the potential use of combination therapy and data on the impact of beta-amyloid imaging on diagnosis and management INDIANAPOLIS , July 8, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that 23 presentations will be given at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark from July 12 – 17, 2014.
Sign-up for Lilly to Showcase Data from its Alzheimer's Disease Portfolio at the Alzheimer's Association International Conference 2014 (AAIC 2014) investment picks
The Medicines Company (NASDAQ:MDCO) today announced that a series of abstracts highlighting data from its Infectious Disease portfolio will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which takes place in Washington, DC from September 5-9, 2014.
Sign-up for The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) investment picks
WOONSOCKET, R.I. , Aug.
Sign-up for CVS Caremark's Accordant Health Services Receives NCQA Disease Management Accreditation investment picks
First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study Trial Designed to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity Multiple Biomarkers to be Assessed DUBLIN, Ireland, July 31, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA) , a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that the first patient with Parkinson's disease has been successfully dosed in a Phase 1 multiple ascending dose clinical trial of PRX002, a potential disease-modifying treatment for Parkinson's disease.
Sign-up for Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease investment picks
Approval aligns with Centers for Disease Control and Prevention's recommendations for meningococcal vaccination SWIFTWATER, Pa.
Sign-up for FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease investment picks
Study Results Presented at the Alzheimer's Association International Conference 2014 INDIANAPOLIS , July 15, 2014 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE:LLY) announced results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of the disease.
Sign-up for New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease investment picks
2014/8/26
Health Net Federal Services, LLC, a wholly owned subsidiary of Health Net, Inc ., announced today it has been awarded full disease management reaccreditation from URAC, a health care accrediting organization that establishes quality standards for the health care industry.
Sign-up for Health Net Federal Services Receives Full URAC Disease Management Reaccreditation investment picks
LOS ANGELES, July 8, 2014 (GLOBE NEWSWIRE) -- RadNet Inc. (Nasdaq:RDNT) , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 250 owned and/or operated outpatient imaging centers, announced it has joined a research study, the Imaging and Genetic Biomarkers for Alzheimer's Disease (ImaGene) study.
Sign-up for RadNet Joins UCLA-Easton Center Alzheimer's Disease Research Study investment picks
Philips Furthers Dialogue and Research on Cardiovascular Disease and Sleep Apnea at ESC Congress 2014 Symposium Builds on Philips' Support for SAVE Study Examining Impact of Obstructive Sleep Apnea Treatment on Cardiovascular Disease Canada NewsWire ANDOVER, Mass.
Sign-up for Philips Furthers Dialogue and Research on Cardiovascular Disease and Sleep Apnea at ESC Congress 2014 investment picks
Study Results Presented at the Alzheimer's Association International Conference 2014 INDIANAPOLIS , July 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that beta-amyloid imaging was associated with altered diagnosis and management of patients with Alzheimer's disease.
Sign-up for New Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimer's Disease investment picks
2014/6/24
Pioneering Angiogenic Gene Therapy for the Potential Treatment of Millions of Patients with Heart Disease Worldwide SAN DIEGO , June 24, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx ® Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.
Sign-up for Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention investment picks
NORCROSS, Ga., June 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that a preclinical study in a mouse model of NASH (non-alcoholic steatohepatitis, or fatty liver disease) demonstrated that oral administration of the Company's lead galectin-3 inhibitor, GR-MD-02, resulted in significant disease improvement.
Sign-up for Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® ( imilecleucel-T ), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today disclosed that the Company has commenced development in a second indication, Neuromyelitis optica (NMO). NMO is a rare autoimmune disorder, which is designated as an Orphan disease by the U.S. Food and Drug Administration (FDA). There is currently no cure and there are no FDA approved therapies for this disease.
Sign-up for Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica (NMO) as next Development Program investment picks
Symposium Builds on Philips' Support for SAVE Study Examining Impact of Obstructive Sleep Apnea Treatment on Cardiovascular Disease ANDOVER, Mass.
Sign-up for Philips Furthers Dialogue and Research on Cardiovascular Disease and Sleep Apnea at ESC Congress 2014 investment picks
JERSEY, Channel Islands, June 23, 2014 (GLOBE NEWSWIRE) -- Quotient Limited ("Quotient") (Nasdaq:QTNT) , a commercial-stage diagnostics company, today announced that results generated using the MosaiQ™ methodology demonstrated a high degree of concordance to predicate technologies screening blood for Cytomegalovirus (CMV) and Syphilis.
Sign-up for Technical Feasibility Established for MosaiQ(TM) CMV and Syphilis Disease Screening Assays investment picks
CINCINNATI , June 23, 2014 /PRNewswire-USNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and Cincinnati Children's Hospital Medical Center today announced the establishment of a collaboration and fund for the advancement of research in rare disease.
Sign-up for Alexion and Cincinnati Children's Launch Rare Disease Innovation Fund investment picks
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease.
Sign-up for Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over Donepezil investment picks
Baxter International Inc. (NYSE:BAX) today announced the acquisition of AesRx, LLC, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD). Aes-103 is a first-in-class, oral, small molecule compound (5-hydroxymethylfurfural). Early studies indicate the compound may work by binding to hemoglobin and increasing oxygen affinity and stabilization, thereby reducing the sickling of red blood cells which, in turn, may reduce sickling-related outcomes such as vaso-occlusive crisis, pain, severe anemia, and fatigue.
Sign-up for Baxter Acquires AesRx, LLC, Including Its Investigational Sickle Cell Disease Treatment investment picks
LA JOLLA, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will present at the 56th Annual Meeting of the Japanese Society of Gastroenterology and the 18th General Meeting of the Japan Society of Hepatology during the Japan Digestive Disease Week (JDDW) 2014 in Kobe, Japan.
Sign-up for MediciNova to Present Data on MN-001 for the Treatment of NASH (Nonalcoholic Steatohepatitis) During the JDDW 2014 (Japan Digestive Disease Week 2014) investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Disease Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Disease Management  |  Next: Display Business